Literature DB >> 10605887

Investigations by HPLC-electrospray mass spectrometry and NMR spectroscopy into the isomerisation of salinomycin.

A L Davis, J A Harris, C A Russell, J P Wilkins.   

Abstract

HPLC-MS studies have indicated that certain polyether ionophore veterinary drugs are prone to degradation when stored as water-methanol solutions at ambient temperature. Salinomycin and narasin were particularly susceptible, disappearing completely within weeks to produce more polar species, which were identified as isomers of the original compounds. Lasalocid appeared to be stable under such conditions. Structural elucidation of the principal ultimate salinomycin isomerisation product was achieved by 2D NMR spectroscopy. This indicated that the isomerisation process consists of the opening of the spiro rings in the salinomycin structure with the concomitant formation of a furan moiety. The MS data indicated that the isomers retain the ability to complex alkali metal ions and may therefore retain their pharmacological activity. These discoveries may have implications both for the development of legislation covering acceptable levels of polyether ionophore residues in foodstuffs and also for analytical protocols designed to detect them.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10605887     DOI: 10.1039/a809594i

Source DB:  PubMed          Journal:  Analyst        ISSN: 0003-2654            Impact factor:   4.616


  2 in total

1.  A comparison of data analysis methods for determining gas phase stabilities by CID: alkali metal complexes of polyether ionophore antibiotics.

Authors:  Matthew W Forbes; Dietrich A Volmer; Gregory J Francis; Diethard K Böhme
Journal:  J Am Soc Mass Spectrom       Date:  2005-05       Impact factor: 3.109

2.  Secondary Metabolites and Biosynthetic Gene Clusters Analysis of Deep-Sea Hydrothermal Vent-Derived Streptomyces sp. SCSIO ZS0520.

Authors:  Huaran Zhang; Yingying Chen; Yanqing Li; Yongxiang Song; Junying Ma; Jianhua Ju
Journal:  Mar Drugs       Date:  2022-06-14       Impact factor: 6.085

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.